U.S. scientists devised a predictive model showing that infant immunization with the 7 valent pneumococcal conjugate vaccine would reduce costs during a normal flu season by $1.4 billion and by $7 billion during a flu pandemic by thwarting bacterial infections. PCV7 vaccination would also prevent 1.24 million pneumonia cases and 357,000 pneumococcal-linked deaths in a pandemic, according to the model.

Related Summaries